Eggermont, Alexander M. M. http://orcid.org/0000-0002-4278-040X
Hamid, Omid http://orcid.org/0000-0002-8238-4655
Long, Georgia V. http://orcid.org/0000-0001-8894-3545
Luke, Jason J. http://orcid.org/0000-0002-1182-4908
Article History
Accepted: 29 March 2022
First Online: 25 April 2022
Competing interests
: A.M.M.E. has served on data safety monitoring boards for Biocad, BioNTech, GlaxoSmithKline (GSK), Novartis and Pfizer; and has served on scientific advisory boards for Agenus, Biocad, BioInvent, CatalYm, Clover, Ellipses, Galecto, GSK, IO Biotech, Merck, Nektar, Sairopa, Sellas, SkylineDx, TigaTx and TTxDiscovery. O.H. has received speaker’s bureau from Bristol Myers Squibb (BMS), Novartis, Pfizer and Sanofi/Regeneron; is a consultant for Aduro, Akeso, Alkermes, Amgen, Beigene, Bioatla, BMS, GSK, lmmunocore, ldera, lncyte, lnstilBio, lovance, Janssen, Merck, NextCure, Novartis, Pfizer, Roche/Genentech, Sanofi/Regeneron, Seattle Genetics, Tempus and Zelluna; and is at a contracted research institution for Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, CytomX, Exelixis, GSK, lmmunocore, ldera, lncyte, lovance, Merck, Moderna, Merck-Serono, NextCure, Novartis, Pfizer, Roche/Genentech, Rubius, Sanofi/Regeneron, Seattle Genetics, Taiga, Torque and Zelluna. G.V.L. is a consultant/adviser for Agenus, Amgen, Array Biopharma, Boehringer Ingelheim, BMS, Evaxion Biotech, Hexal AG (Sandoz Company), Highlight Therapeutics, Merck Sharpe & Dohme, Novartis, OncoSec, Pierre Fabre, Provectus, Qbiotics and Regeneron. J.J.L. has served on data safety monitoring boards for Abbvie, Immutep and Evaxion. He has served on scientific advisory boards without equity consideration for 7 Hills, Bright Peak, Exo, Fstar, Inzen, RefleXion and Xilio, and with equity consideration for Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, Pyxis, Stipe and Tempest. He has held consultancy roles with compensation for Abbvie, Alnylam, Bayer, BMS, Castle, Checkmate, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, HotSpot, Ikena, Immunocore, Incyte, Janssen, Kadmon, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Regeneron, Servier, STINGthera, Synlogic and Synthekine. He has received research support (all to his institution for clinical trials unless noted) from AbbVie, Astellas, AstraZeneca, BMS (for both investigator-initiated and industry trials), Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, NextCure, Numab, Palleon, Pfizer (investigator-initiated and industry trials), Replimmune, Rubius, Servier (investigator-initiated trials), Scholar Rock, Synlogic, Takeda, Tizona, Trishula and Xencor. He holds intellectual property on the following patents: Serial #15/612,657 (Cancer Immunotherapy); PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).